World’s Biggest L-DOPA Production Base Ready For Operation
This article was originally published in PharmAsia News
Executive Summary
Shandong Xinhua Pharmaceutical Co. Ltd. and Sankyo Chemical Industries Ltd. held a completion ceremony for their joint L-380 (drug name L-DOPA) project in Zibo city, Shandong province on Dec. 23. Initial production is to begin in early 2008 with a yearly output of 300 tonnes. The project will be the world's biggest L-380 production base when in full operation. L-DOPA, used for treating Parkinson's disease, is expected to grow at an annual rate of 13 percent globally to reach $2.3 billion by 2010. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.